{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:25:01Z","timestamp":1789709101208,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.clinthera.2016.03.002","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T12:18:56Z","timestamp":1459599536000},"page":"759-768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct00853047","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Heather L.","family":"Gelhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u2019Dorisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi M.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi A.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Kostelec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Auguste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2016.03.002_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","article-title":"Epidemiology of neuroendocrine tumours","volume":"80","author":"Taal","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clinthera.2016.03.002_bib2","doi-asserted-by":"crossref","unstructured":"Choti MA, Bobiak S, Strosberg JR, et al. Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database. Presented at the 2012 Neuroendocrine Tumor Symposium; October 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.4126"},{"key":"10.1016\/j.clinthera.2016.03.002_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00001610-200205000-00004","article-title":"Carcinoid tumors and syndrome","volume":"25","author":"McCormick","year":"2002","journal-title":"Gastroenterol Nurs"},{"key":"10.1016\/j.clinthera.2016.03.002_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid\u2014a comprehensive review","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clinthera.2016.03.002_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Evaluation of telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clinthera.2016.03.002_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1677\/erc.0.0100483","article-title":"Measurement of quality of life in carcinoid\/neuroendocrine tumours","volume":"10","author":"Ramage","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clinthera.2016.03.002_bib7","unstructured":"European Organization for Research and Treatment of Cancer. EORTC QOL module for carcinoid\/neuroendocrine tumours: EORTC QLQ-G.I.NET21. http:\/\/groups.eortc.be\/qol\/carcinoid-neuroendocrine-tumours-qlq-ginet21. Accessed December 22, 2015."},{"key":"10.1016\/j.clinthera.2016.03.002_bib8","unstructured":"EORTC QLQ-C30. http:\/\/groups.eortc.be\/qol\/eortc-qlq-c30. Accessed December 22, 2015."},{"key":"10.1016\/j.clinthera.2016.03.002_bib9","series-title":"User\u2019s Manual for ATLAS.ti 5.0.","author":"Muhr","year":"2004"},{"key":"10.1016\/j.clinthera.2016.03.002_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1\u2014eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2016.03.002_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","article-title":"Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment","volume":"26","author":"Leidy","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2016.03.002_bib12","unstructured":"Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values. http:\/\/groups.eortc.be\/qol\/sites\/default\/files\/img\/newsletter\/reference_values_manual2008.pdf. Accessed January 11, 2016."},{"key":"10.1016\/j.clinthera.2016.03.002_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/cli.15.10","article-title":"Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome","volume":"5","author":"Lapuerta","year":"2015","journal-title":"Clin Invest"},{"key":"10.1016\/j.clinthera.2016.03.002_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.2012.560","article-title":"Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours","volume":"108","author":"Yadegarfar","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2016.03.002_bib16","unstructured":"Curtis P, Slaughter-Mason S, Thielke A, et al. PCORI Expert Interviews Project Final Report. http:\/\/www.pcori.org\/sites\/default\/files\/ExpertInterviewsPart1.pdf. Accessed February 22, 2016."},{"key":"10.1016\/j.clinthera.2016.03.002_bib17","unstructured":"MedlinePlus. 5-HIAA. http:\/\/www.nlm.nih.gov\/medlineplus\/ency\/article\/003612.htm. Accessed April 24, 2013."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816301229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816301229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T02:59:10Z","timestamp":1600397950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816301229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0149291816301229"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Lexicon Pharmaceuticals. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}